S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

USANA Health Sciences Stock Price, News & Analysis (NYSE:USNA)

$47.26
+0.56 (+1.20%)
(As of 11/30/2023 ET)
Compare
Today's Range
$46.06
$47.40
50-Day Range
$44.45
$60.40
52-Week Range
$44.01
$69.60
Volume
73,987 shs
Average Volume
69,205 shs
Market Capitalization
$904.08 million
P/E Ratio
15.29
Dividend Yield
N/A
Price Target
$53.00

USANA Health Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
12.1% Upside
$53.00 Price Target
Short Interest
Healthy
1.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$22,545 Sold Last Quarter
Proj. Earnings Growth
-1.02%
From $2.94 to $2.91 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

775th out of 948 stocks

Medicinals & Botanicals Industry

6th out of 12 stocks


USNA stock logo

About USANA Health Sciences Stock (NYSE:USNA)

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

USNA Stock Price History

USNA Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Q3 2023 USANA Health Sciences Inc Earnings Call
USANA Health Sciences Reports Decline In Q3 Income, misses estimates
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
USANA Health Sciences Reports Third Quarter 2023 Results
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
Usana Health Sciences's Earnings: A Preview
USNA or STVN: Which Is the Better Value Stock Right Now?
Kevin Guest Shares 5 Benefits of Returning to Office
USNA vs. ZTS: Which Stock Is the Better Value Option?
USANA HR Professional Recognized for Excellence
See More Headlines
Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/24/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/06/2024

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
Personal Products
Sector
Medical
CUSIP
90328M10
Employees
1,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$53.00
High Stock Price Target
$53.00
Low Stock Price Target
$53.00
Potential Upside/Downside
+12.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$69.35 million
Pretax Margin
10.63%

Debt

Sales & Book Value

Annual Sales
$998.60 million
Cash Flow
$4.79 per share
Book Value
$24.59 per share

Miscellaneous

Free Float
19,067,000
Market Cap
$899.68 million
Optionable
Optionable
Beta
0.82
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














USNA Stock Analysis - Frequently Asked Questions

Should I buy or sell USANA Health Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" USNA shares.
View USNA analyst ratings
or view top-rated stocks.

What is USANA Health Sciences' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price targets for USANA Health Sciences' shares. Their USNA share price targets range from $53.00 to $53.00. On average, they anticipate the company's share price to reach $53.00 in the next year. This suggests a possible upside of 12.1% from the stock's current price.
View analysts price targets for USNA
or view top-rated stocks among Wall Street analysts.

How have USNA shares performed in 2023?

USANA Health Sciences' stock was trading at $53.20 on January 1st, 2023. Since then, USNA shares have decreased by 11.2% and is now trading at $47.26.
View the best growth stocks for 2023 here
.

When is USANA Health Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our USNA earnings forecast
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its earnings results on Tuesday, October, 24th. The company reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.64 by $0.05. The firm had revenue of $213.37 million for the quarter, compared to the consensus estimate of $212.24 million. USANA Health Sciences had a net margin of 6.45% and a trailing twelve-month return on equity of 13.08%.

What ETFs hold USANA Health Sciences' stock?
What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences updated its FY23 earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $2.80-3.05 for the period, compared to the consensus estimate of $3.13. The company issued revenue guidance of $900-920 million, compared to the consensus revenue estimate of $930.04 million.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Pzena Investment Management LLC (4.08%), Charles Schwab Investment Management Inc. (1.11%), Acadian Asset Management LLC (0.90%), American Century Companies Inc. (0.71%), Invesco Ltd. (0.64%) and Bank of New York Mellon Corp (0.60%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood, Walter Noot and Xia Ding.
View institutional ownership trends
.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:USNA) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -